Chemomab Therapeutics
CMMB
12 hedge funds and large institutions have $2.27M invested in Chemomab Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% less ownership
Funds ownership: 0.29% → 0.29% (-0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
32% less capital invested
Capital invested by funds: $3.34M → $2.27M (-$1.07M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWA
Moser Wealth Advisors
Bellevue,
Washington
|
+$584 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$150 |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$51 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.11K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$187 |
| 3 |
Morgan Stanley
New York
|
-$132 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $2.01M | – | – | – |
|
|
IC
2
Ikarian Capital
Dallas,
Texas
| $191K | – | – | – |
|
|
KPWS
3
Kestra Private Wealth Services
Austin,
Texas
| $28K | – | – | – |
|
|
BFM
4
Boothbay Fund Management
New York
| $23.7K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $10.5K | – | – | – |
|
|
ASN
6
Advisory Services Network
Atlanta,
Georgia
| $10K | – | – | – |
|
|
7
RhumbLine Advisers
Boston,
Massachusetts
| $2.54K | -$187 | -40 | -5% |
|
|
8
Osaic Holdings
Scottsdale,
Arizona
| $1.59K | -$1.11K | -237 | -35% |
|
|
NFSG
9
Newbridge Financial Services Group
Boca Raton,
Florida
| $985 | – | – | – |
|
|
MWA
10
Moser Wealth Advisors
Bellevue,
Washington
| $448 | +$584 | +125 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| $126 | +$150 | +32 | +1,067% |
|
|
12
Qube Research & Technologies (QRT)
London,
United Kingdom
| $39 | +$51 | +11 | New |
|
|
13
Morgan Stanley
New York
| – | -$132 | -25 | Closed |
|
CMMB Hedge Fund Activity: Q3 2023 in Review
12 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q3 2023, worth a combined $2.27M — down 32% from $3.34M a quarter earlier.
Fund positioning in CMMB was balanced in Q3 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Moser Wealth Advisors, opening a new position worth an estimated $584. The largest seller was Osaic Holdings, cutting an estimated $1.11K.
- 12 institutional investors held Chemomab Therapeutics (CMMB) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $2.27M of Chemomab Therapeutics stock for Q3 2023, down 32% quarter-over-quarter.
- 2 funds opened new Chemomab Therapeutics positions in Q3 2023 and 2 closed out, a net change of 0 holders.
- The largest Chemomab Therapeutics buyer in Q3 2023 was Moser Wealth Advisors, an estimated $584 added.
- The largest Chemomab Therapeutics seller in Q3 2023 was Osaic Holdings, an estimated $1.11K sold.
Based on aggregated 13F filings for Q3 2023.